Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
34 hedge funds and large institutions have $450M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 6 closing their positions.
67% more capital invested
Capital invested by funds: $270M → $450M (+$180M)
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 32 → 34 (+2)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Temasek Holdings
Singapore
|
+$114M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.9M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
+$10.1M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$3.27M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
+$1.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.33M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.04M |
| 3 |
CCM
CloudAlpha Capital Management
Hong Kong
|
-$2.54M |
| 4 |
ZP
Zimmer Partners
New York
|
-$910K |
| 5 |
Morgan Stanley
New York
|
-$808K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| $187K | +$159K | +13,454 | +134,540% |
|
|
BFM
27
Boothbay Fund Management
New York
| $163K | -$26.7K | -2,261 | -16% |
|
28
Vontobel Holding
Zurich,
Switzerland
| $139K | – | – | – |
|
29
Daiwa Securities Group
Tokyo,
Japan
| $66K | +$56.2K | +4,764 | New |
|
30
Citigroup
New York
| $14K | -$14.8K | -1,254 | -56% |
|
|
TCM
31
TD Capital Management
Memphis,
Tennessee
| $5K | – | – | – |
|
|
EBA
32
Eagle Bay Advisors
New York
| $2K | – | – | – |
|
33
Fidelity Investments
Boston,
Massachusetts
| $1K | -$13.4K | -1,135 | -92% |
|
34
JP Morgan Chase
New York
| $1K | +$956 | +81 | New |
|
|
SFM
35
Sphera Funds Management
Tel Aviv,
Israel
| – | -$3.04M | -233,850 | Closed |
|
|
ZP
36
Zimmer Partners
New York
| – | -$910K | -70,000 | Closed |
|
|
NSRI
37
New Silk Road Investment
Singapore
| – | -$650K | -50,000 | Closed |
|
|
SSA
38
Schonfeld Strategic Advisors
New York
| – | -$486K | -37,413 | Closed |
|
39
D.E. Shaw & Co
New York
| – | -$200K | -15,356 | Closed |
|
40
UBS Group
Zurich,
Switzerland
| – | -$5K | -422 | Closed |
|
GRCL Hedge Fund Activity: Q3 2021 in Review
34 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q3 2021, worth a combined $450M — up 67% from $270M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GRCL positions and 6 closed out — a net gain of 2 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Temasek Holdings, adding an estimated $114M. The largest seller was Vivo Capital, cutting an estimated $4.33M.
- 34 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q3 2021, up from 32 in Q2 2021.
- Funds reported $450M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q3 2021, up 67% quarter-over-quarter.
- 8 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q3 2021 and 6 closed out, a net change of +2 holders.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q3 2021 was Temasek Holdings, an estimated $114M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q3 2021 was Vivo Capital, an estimated $4.33M sold.
Based on aggregated 13F filings for Q3 2021.